Korean J Pediatr Gastroenterol Nutr.  2004 Sep;7(2):197-207.

Three Years' Cumulative Therapeutic Efficacy and Long-term Durability of Lamivudine in Korean Children with Chronic Hepatitis B

• Jang YC
• Cho MH
• Choe BH

Abstract

PURPOSE: To evaluate the long-term therapeutic efficacy and durability of lamivudine in Korean children with chronic hepatitis B.
METHODS
A total of 48 children (31 male and 17 female; age, 1~18 years, mean, 8 years) with chronic hepatitis B who received lamivudine for at least six months from March 1999 to September 2004 were followed for a mean period of 29 months (8~66 months) at Department of Pediatrics, Kyungpook National University Hospital in Korea. Response to treatment was defined as the normalization of ALT and HBV DNA levels, and HBeAg seroconversion after the initiation of treatment.
RESULTS
Twenty nine (60%) among the 48 children treated with lamivudine responded and nine (19%) children lost HBsAg during therapy. ALT and HBV DNA level had normalized in 94% one year after the initiation of treatment. Kaplan-Meier estimates of cumulative HBeAg seroconversion rates over the years were 13% (0.5 year), 34% (1 year), 50% (1.5 years), 68% (2 years), 79% (2.5 years) and 90% at 3 years respectively. Above all, among the 22 children treated before the age of seven, loss of HBsAg occurred in eight (36%), which showed superior rate of HBsAg loss (p=0.002 vs age >7).
CONCLUSION
Long-term treatment of lamivudine improved the rate of HBeAg seroconversion in Korean children with chronic hepatitis B. After three years' observation, most of treated children have sustained HBeAg clearance. We believe that lamivudine should be tried as the first therapeutic option for children with chronic hepatitis B in immune clearance phase.

Keyword

Chronic hepatitis B; Children; Lamivudine; Hepatitis B e Antigens; Hepatitis B s Antigens; Seroconversion; Treatment

MeSH Terms

Child*
DNA
Female
Gyeongsangbuk-do
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Hepatitis B, Chronic*
Hepatitis, Chronic*
Humans
Korea
Lamivudine*
Male
Pediatrics
DNA
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Lamivudine